Cardiomyopathy

Cardiomyopathy – Medical Student Study Guide

Cardiomyopathies are a heterogeneous group of myocardial diseases that lead to structural and functional abnormalities of the heart muscle, often causing heart failure, arrhythmias, and sudden cardiac death. Early recognition and classification are crucial for prognosis, family screening, and targeted therapy. Emerging imaging and molecular tools, including 3D modeling and strain imaging, are reshaping diagnosis and management of hypertrophic and infiltrative forms. [1](https://pubmed.ncbi.nlm.nih.gov/41817303/) [5](https://pubmed.ncbi.nlm.nih.gov/41309713/) [8](https://europepmc.org/article/MED/41830166)

Definition

Cardiomyopathy refers to diseases of the heart muscle characterized by mechanical and/or electrical dysfunction, usually with inappropriate ventricular hypertrophy or dilatation, in the absence of other cardiac conditions (e.g., coronary artery disease, hypertension, valvular disease, congenital disease) that alone can explain the observed abnormality. It is generally classified into:

• Dilated cardiomyopathy (DCM): Ventricular dilatation with systolic dysfunction.
• Hypertrophic cardiomyopathy (HCM): Unexplained LV hypertrophy, often asymmetric, with or without LV outflow tract (LVOT) obstruction.
• Restrictive cardiomyopathy (RCM): Non-dilated ventricles with impaired diastolic filling and normal or near-normal systolic function.
• Arrhythmogenic right ventricular cardiomyopathy (ARVC): Fibrofatty replacement of myocardium, predominantly RV, causing arrhythmias.
• Infiltrative / storage cardiomyopathies: Myocardial involvement by systemic diseases (e.g., transthyretin amyloidosis, sarcoidosis, hemochromatosis, Fabry disease). [5](https://pubmed.ncbi.nlm.nih.gov/41309713/) [8](https://europepmc.org/article/MED/41830166)

Epidemiology

Epidemiology varies by subtype and geography, but cardiomyopathies as a group are a major cause of heart failure and sudden cardiac death in younger patients and athletes.

• DCM: The most common cardiomyopathy; prevalence roughly 1:250–1:500 in the general population. Idiopathic and familial forms are frequent.
• HCM: Prevalence around 1:200–1:500, often inherited in an autosomal dominant fashion with variable penetrance. It is a leading cause of sudden cardiac death in young athletes. [7](https://europepmc.org/article/PMC/PMC12986534)
• RCM: Less common; often secondary to infiltrative or systemic diseases such as amyloidosis, which is increasingly recognized with advanced imaging tools. [5](https://pubmed.ncbi.nlm.nih.gov/41309713/) [8](https://europepmc.org/article/MED/41830166)
• ARVC: Relatively rare but important cause of ventricular arrhythmias and sudden death in young individuals and athletes.
• Infiltrative cardiomyopathies (e.g., ATTR amyloidosis): Previously underdiagnosed but now recognized more frequently in older adults due to improved imaging and specific biomarkers. [5](https://pubmed.ncbi.nlm.nih.gov/41309713/) [8](https://europepmc.org/article/MED/41830166)

Pathophysiology

Dilated Cardiomyopathy (DCM)

DCM is characterized by ventricular chamber dilation and systolic dysfunction (reduced ejection fraction). Etiologies include genetic mutations (sarcomeric, cytoskeletal, mitochondrial proteins), myocarditis, toxins (e.g., alcohol, chemotherapy), metabolic/endocrine causes (e.g., diabetes), and peripartum cardiomyopathy. Progressive myocyte injury and death, extracellular matrix remodeling, and neurohormonal activation (RAAS, sympathetic system) lead to chamber enlargement, spherical remodeling, and functional mitral regurgitation, culminating in chronic heart failure.

Hypertrophic Cardiomyopathy (HCM)

HCM is usually caused by autosomal dominant mutations in sarcomeric proteins (e.g., beta-myosin heavy chain, myosin-binding protein C), leading to myocyte hypertrophy, disarray, and interstitial fibrosis. Asymmetric septal hypertrophy is typical and can create dynamic LVOT obstruction, particularly with systolic anterior motion (SAM) of the mitral valve. This results in increased LV filling pressures, impaired diastolic relaxation, ischemia (due to increased wall stress and microvascular dysfunction), and arrhythmogenic substrate. Advanced 3D imaging and modeling allow precise visualization of septal morphology (e.g., W-shaped interventricular septum) and guide tailored septal reduction therapy. [1](https://pubmed.ncbi.nlm.nih.gov/41817303/) [6](https://europepmc.org/article/MED/41817303)

Restrictive Cardiomyopathy (RCM) and Infiltrative Disease

RCM is characterized by stiff, non-compliant ventricles with impaired diastolic filling and preserved or mildly reduced systolic function. Common causes include amyloidosis, endomyocardial fibrosis, radiation, and storage diseases.

• Transthyretin (ATTR) amyloidosis: Misfolded transthyretin proteins form amyloid fibrils that deposit in the myocardium, causing increased wall thickness, impaired relaxation, conduction system disease, and heart failure with preserved EF (HFpEF) phenotype. Left ventricular mechanical dispersion assessed by strain echocardiography correlates with disease severity and arrhythmic risk. [5](https://pubmed.ncbi.nlm.nih.gov/41309713/) [8](https://europepmc.org/article/MED/41830166)
• Other infiltrative diseases (e.g., sarcoidosis, hemochromatosis) cause granulomatous or iron deposition, respectively, leading to fibrotic remodeling and arrhythmogenic substrate.

Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

ARVC is usually due to desmosomal gene mutations (e.g., plakophilin-2, desmoglein-2) that impair cell-cell adhesion. Mechanical stress causes myocyte detachment, death, and replacement by fibrofatty tissue, predominantly in the RV free wall and outflow tract. This substrate supports re-entrant ventricular arrhythmias and progressive RV dysfunction; LV involvement occurs in advanced disease.

Diabetic Cardiomyopathy and Metabolic Factors

Diabetic cardiomyopathy is a distinct entity characterized by myocardial dysfunction in the absence of overt coronary artery disease or hypertension. Chronic hyperglycemia, lipotoxicity, oxidative stress, and low-grade inflammation lead to myocardial fibrosis, microvascular dysfunction, and diastolic then systolic impairment. Ubiquitin-specific proteases (e.g., USP20) can modulate inflammatory pathways; experimental data suggest that cardiomyocyte USP20 attenuates diabetic cardiomyopathy by promoting degradation of STING, a key mediator of innate immune signaling, thereby reducing inflammation and myocardial injury. [2](https://pubmed.ncbi.nlm.nih.gov/41637663/) [4](https://pubmed.ncbi.nlm.nih.gov/41471379/)

Clinical Presentation

Clinical manifestations depend on the cardiomyopathy subtype, degree of dysfunction, and presence of arrhythmias or systemic disease.

Common Symptoms

• Dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea (HF symptoms).
• Fatigue and exercise intolerance.
• Palpitations, presyncope, or syncope (often arrhythmia-related).
• Peripheral edema, ascites, abdominal discomfort (right-sided HF).
• Chest pain or angina-like symptoms, especially in HCM and infiltrative disease.

Physical Examination Findings

• DCM: Displaced, diffuse apical impulse; S3 gallop; holosystolic MR murmur; signs of volume overload (rales, JVD, edema).
• HCM: Forceful, bifid apical impulse; systolic ejection murmur that increases with maneuvers that decrease preload (e.g., Valsalva, standing); S4 gallop; possible carotid upstroke abnormalities.
• RCM / Amyloidosis: Elevated JVP with prominent y descent, Kussmaul sign, S3 or S4; relatively small or normal ventricular size with marked HF symptoms.
• ARVC: Often normal auscultation; may have RV heave, S3, or TR murmur in advanced disease; ventricular ectopy on exam or telemetry.

Red Flags

• Unexplained syncope, especially with exertion.
• Family history of sudden cardiac death or cardiomyopathy.
• Young athlete with exertional chest pain, dyspnea, or presyncope.
• Rapidly progressive HF, especially with low blood pressure or arrhythmias.

Diagnosis

Diagnosis requires integration of clinical evaluation, imaging, ECG findings, and often genetic and histologic data. Advanced imaging techniques (3D echocardiography, strain imaging, cardiac MRI) and targeted molecular testing are increasingly central in characterizing phenotype and guiding treatment. [1](https://pubmed.ncbi.nlm.nih.gov/41817303/) [5](https://pubmed.ncbi.nlm.nih.gov/41309713/) [8](https://europepmc.org/article/MED/41830166)

Initial Evaluation

• History and exam: Focus on HF symptoms, syncope, arrhythmias, drug and toxin exposure, systemic disease, and detailed family history (3 generations).
• ECG: May reveal LVH (HCM, amyloidosis), conduction defects, atrial fibrillation, pathologic Q waves, epsilon waves (ARVC), or low voltage (amyloidosis).
• Chest X-ray: Can show cardiomegaly, pulmonary congestion, or pleural effusions in DCM; may be normal in early HCM or ARVC.
• Baseline labs: CBC, CMP, thyroid function, BNP/NT-proBNP, troponin when indicated; screen for metabolic and systemic causes (iron studies, HIV, etc.) as appropriate.

Echocardiography

Transthoracic echocardiogram (TTE) is the cornerstone of initial imaging.

• DCM: Dilated LV (and often RV), reduced LVEF, global hypokinesis, functional MR/TR.
• HCM: Asymmetric septal hypertrophy, small LV cavity, SAM of the mitral valve; dynamic LVOT obstruction quantified by continuous-wave Doppler; diastolic dysfunction.
• RCM / Amyloidosis: Increased wall thickness with normal cavity size, biatrial enlargement, restrictive filling pattern; speckled or granular appearance; reduced longitudinal strain with apical sparing in amyloidosis. LV mechanical dispersion on strain imaging correlates with disease severity in transthyretin amyloidosis. [5](https://pubmed.ncbi.nlm.nih.gov/41309713/)
• ARVC: RV dilation or regional akinesia/dyskinesia, reduced RV function; imaging features are often better characterized by cardiac MRI.

Advanced Imaging

• Cardiac MRI (CMR): Provides detailed anatomy, function, and tissue characterization. Late gadolinium enhancement (LGE) patterns help differentiate ischemic from non-ischemic scars and identify infiltrative or inflammatory disease. It is particularly useful in ARVC, myocarditis, and infiltrative cardiomyopathies. [3](https://pubmed.ncbi.nlm.nih.gov/41576848/) [8](https://europepmc.org/article/MED/41830166)
• 3D echocardiography and modeling: Allow accurate assessment of complex septal anatomy in HCM, such as W-shaped interventricular septal phenotypes, and guide patient-specific septal reduction strategies. [1](https://pubmed.ncbi.nlm.nih.gov/41817303/) [6](https://europepmc.org/article/MED/41817303)
• Nuclear imaging: Bone scintigraphy (e.g., Tc-99m–labeled tracers) is increasingly used for non-invasive diagnosis of ATTR amyloid cardiomyopathy in the appropriate clinical context. [5](https://pubmed.ncbi.nlm.nih.gov/41309713/) [8](https://europepmc.org/article/MED/41830166)

Genetic Testing and Family Screening

• Consider in HCM, idiopathic DCM, ARVC, and some RCM/infiltrative forms.
• Helps refine diagnosis, guide prognosis, and identify at-risk relatives for surveillance and early intervention.
• Should ideally be accompanied by genetic counseling.

Biopsy and Histopathology

• Endomyocardial biopsy: Reserved for specific indications: unexplained fulminant HF, suspected myocarditis, infiltrative diseases when non-invasive testing is inconclusive, or histiocytic myocarditis causing cardiogenic shock. [3](https://pubmed.ncbi.nlm.nih.gov/41576848/)
• Histologic patterns can reveal myocyte disarray (HCM), amyloid deposition, granulomas (sarcoidosis), iron deposition, or histiocytic infiltrates.

Management

Management is tailored to the specific cardiomyopathy subtype, underlying etiology, degree of LV dysfunction, and arrhythmic risk. Principles include disease-modifying therapy, standard HF management, arrhythmia prevention, and lifestyle/counseling (including sports participation). [5](https://pubmed.ncbi.nlm.nih.gov/41309713/) [7](https://europepmc.org/article/PMC/PMC12986534/) [8](https://europepmc.org/article/MED/41830166)

General Measures

• Treat precipitating causes and comorbidities: hypertension, ischemia, valvular disease, diabetes, thyroid disease, sleep apnea.
• Limit alcohol and avoid cardiotoxic drugs (e.g., certain chemotherapeutics) when possible.
• Diuretics for symptomatic volume overload.
• Vaccinations (influenza, pneumococcal) as per HF guidelines.

Guideline-Directed Medical Therapy (GDMT) for HFrEF Phenotypes (e.g., DCM)

• ACE inhibitors/ARBs/ARNIs: Reduce afterload, improve symptoms and survival.
• Beta-blockers: Decrease sympathetic activation, improve LV function, reduce arrhythmias and mortality.
• Mineralocorticoid receptor antagonists: Reduce remodeling, HF hospitalizations, and mortality.
• SGLT2 inhibitors: Provide additional morbidity and mortality benefit in HFrEF regardless of diabetes status.

Hypertrophic Cardiomyopathy (HCM)

• Symptom control:
  • Beta-blockers are first-line for angina, dyspnea, and palpitations.
  • Non-dihydropyridine calcium channel blockers (verapamil, diltiazem) as alternatives if beta-blockers not tolerated.
  • Disopyramide may be added for additional LVOT gradient reduction in obstructive HCM.
• Septal reduction therapy:
  • Surgical septal myectomy is indicated in symptomatic patients with severe LVOT obstruction despite optimal medical therapy. 3D imaging and modeling of LV and septal geometry (e.g., W-shaped septum) help plan tailored resections and avoid complications. [1](https://pubmed.ncbi.nlm.nih.gov/41817303/) [6](https://europepmc.org/article/MED/41817303)
  • Alcohol septal ablation offers a catheter-based alternative in selected patients.
• Arrhythmia and SCD prevention:
  • Risk stratify for sudden death using family history, syncope, massive LVH, non-sustained VT, and imaging markers.
  • Implantable cardioverter-defibrillator (ICD) for patients at high SCD risk (primary or secondary prevention).
• Activity counseling:
  • Restrict high-intensity competitive sports in high-risk individuals; individualized clearance protocols for athletes. [7](https://europepmc.org/article/PMC/PMC12986534)

Restrictive and Infiltrative Cardiomyopathies

• Heart failure management: Diuretics for congestion; careful balancing to avoid underfilling stiff ventricles.
• Etiology-specific therapy:
  • Transthyretin amyloidosis: TTR stabilizers and emerging gene-silencing therapies; early identification using strain imaging and nuclear techniques is key. [5](https://pubmed.ncbi.nlm.nih.gov/41309713/) [8](https://europepmc.org/article/MED/41830166)
  • Hemochromatosis: Iron chelation or phlebotomy.
  • Sarcoidosis: Immunosuppression (e.g., corticosteroids) in active inflammatory disease.
  • Storage diseases: Enzyme replacement or substrate reduction therapy where available.
• Advanced therapies: Pacemakers or ICDs for conduction disease and ventricular arrhythmias; consideration of transplantation in refractory cases.

Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

• Antiarrhythmic drugs (e.g., sotalol, amiodarone) for symptomatic ventricular arrhythmias.
• ICD implantation in patients with sustained VT, aborted SCD, or high-risk features.
• Catheter ablation for recurrent VT, often as adjunct to ICD therapy.
• Restriction from competitive endurance sports and high-intensity exercise.

Diabetic and Metabolic Cardiomyopathies

• Intensive risk factor control: glycemic, blood pressure, lipid management.
• SGLT2 inhibitors and possibly GLP-1 receptor agonists for cardiometabolic benefit.
• Emerging molecular targets (e.g., modulation of STING pathway, anti-inflammatory strategies) are under investigation for future therapies. [2](https://pubmed.ncbi.nlm.nih.gov/41637663/) [4](https://pubmed.ncbi.nlm.nih.gov/41471379/)

Advanced and Definitive Therapies

• Cardiac resynchronization therapy (CRT) in selected patients with HFrEF and conduction delay.
• Left ventricular assist devices (LVADs) as bridge to transplant or destination therapy in end-stage DCM and some other forms.
• Heart transplantation for refractory, advanced cardiomyopathy not amenable to other therapies.
• Emerging gene and molecular therapies for genetic and infiltrative cardiomyopathies, targeting specific pathways and protein misfolding. [8](https://europepmc.org/article/MED/41830166)

Key Clinical Pearls

• Think cardiomyopathy in younger patients with unexplained HF, arrhythmias, or family history of sudden death, and in athletes with exertional syncope or chest pain. [7](https://europepmc.org/article/PMC/PMC12986534)
• Echocardiography is your first-line tool, but not the last word: use CMR, strain imaging, and 3D modeling to refine phenotype, especially in HCM, ARVC, and infiltrative diseases. [1](https://pubmed.ncbi.nlm.nih.gov/41817303/) [5](https://pubmed.ncbi.nlm.nih.gov/41309713/) [8](https://europepmc.org/article/MED/41830166)
• Family screening and genetics are critical in HCM, ARVC, and idiopathic DCM; early identification of at-risk relatives can prevent SCD.
• Infiltrative cardiomyopathies are increasingly treatable if recognized early; look for red flags like discordant low-voltage ECG with increased wall thickness on echo (amyloidosis pattern). [5](https://pubmed.ncbi.nlm.nih.gov/41309713/) [8](https://europepmc.org/article/MED/41830166)
• Dynamic murmurs matter in HCM: LVOT obstruction murmur increases with decreased preload (Valsalva, standing) and decreases with increased afterload or preload (handgrip, squatting).
• Cardiomyopathy is not one disease: distinguishing subtype and etiology is essential because many have targeted therapies (e.g., TTR stabilizers for amyloid, immunosuppression for sarcoid, chelation for hemochromatosis, gene-directed therapies under development). [5](https://pubmed.ncbi.nlm.nih.gov/41309713/) [8](https://europepmc.org/article/MED/41830166)
• Cardiogenic shock in the setting of myocarditis should prompt consideration of rare forms like histiocytic myocarditis; biopsy can be diagnostic and guide management. [3](https://pubmed.ncbi.nlm.nih.gov/41576848/)

This framework equips medical students to approach cardiomyopathy systematically: recognize clinical patterns, classify by phenotype and etiology, apply appropriate diagnostic tools, and understand major therapeutic strategies, including emerging molecular and gene-directed interventions.